Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
Cancer Biotherapy and Radiopharmaceuticals coverage includes:
- Antibody drug conjugates
- Fusion toxins and immunotoxins
- Nanoparticle therapy
- Vascular therapy
- Inhibitors of proliferation signaling pathways
Cancer Biotherapy and Radiopharmaceuticals is under the editorial leadership of Editors Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham; Robert K. Oldham, MD, CAMC-Teay’s Valley Cancer Center; and other leading investigators. View the entire editorial board.
Audience: Oncologists, nuclear medicine researchers, radiologists, cancer researchers, pathologists, and epidemiologists, among others.
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.